Format

Send to

Choose Destination
See comment in PubMed Commons below
Diabetes. 2014 Oct;63(10):3210-20. doi: 10.2337/db14-0144. Epub 2014 Jun 19.

Peroxiredoxin 6, a novel player in the pathogenesis of diabetes.

Author information

  • 1Department of System Medicine, University of Rome Tor Vergata, Rome, Italy.
  • 2Division of Endocrinology and Metabolic Diseases, Universit√† Cattolica del Sacro Cuore, Rome, Italy Diabetic Care Clinics, Associazione dei Cavalieri Italiani Sovrano Militare Ordine di Malta, Rome, Italy.
  • 3Anatomic Pathology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • 4Department of System Medicine, University of Rome Tor Vergata, Rome, Italy Institute of Translational Pharmacology, National Research Council, Rome, Italy.
  • 5Department of System Medicine, University of Rome Tor Vergata, Rome, Italy Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy.
  • 6Division of Endocrinology and Metabolic Diseases, Universit√† Cattolica del Sacro Cuore, Rome, Italy Fondazione Don Carlo Gnocchi, Milan, Italy.
  • 7Department of System Medicine, University of Rome Tor Vergata, Rome, Italy d.lauro@med.uniroma2.it.

Abstract

Enhanced oxidative stress contributes to the pathogenesis of diabetes and its complications. Peroxiredoxin 6 (PRDX6) is a key regulator of cellular redox balance, with the peculiar ability to neutralize peroxides, peroxynitrite, and phospholipid hydroperoxides. In the current study, we aimed to define the role of PRDX6 in the pathophysiology of type 2 diabetes (T2D) using PRDX6 knockout (-/-) mice. Glucose and insulin responses were evaluated respectively by intraperitoneal glucose and insulin tolerance tests. Peripheral insulin sensitivity was analyzed by euglycemic-hyperinsulinemic clamp, and molecular tools were used to investigate insulin signaling. Moreover, inflammatory and lipid parameters were evaluated. We demonstrated that PRDX6(-/-) mice developed a phenotype similar to early-stage T2D caused by both reduced glucose-dependent insulin secretion and increased insulin resistance. Impaired insulin signaling was present in PRDX6(-/-) mice, leading to reduction of muscle glucose uptake. Morphological and ultrastructural changes were observed in islets of Langerhans and livers of mutant animals, as well as altered plasma lipid profiles and inflammatory parameters. In conclusion, we demonstrated that PRDX6 is a key mediator of overt hyperglycemia in T2D glucose metabolism, opening new perspectives for targeted therapeutic strategies in diabetes care.

© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk